 
A Randomized, Double Blind, Placebo Controlled Study to Evaluate the 
Efficacy and Safety of Ampligen® in Patients  with Post -COVID Conditions   
Protocol Number:  AMP -518 
Version:  Version 4.0 
Date:  23-Aug-2023  
  
 
Sponsor:  AIM ImmunoTech Inc.  
[ADDRESS_536000] 484  
Ocala, FL [ZIP_CODE], [LOCATION_003]  
 
 
 
 
Clinical Trials.gov Identifier: [STUDY_ID_REMOVED]  
 
 
Confidentiality Statement  
 
This document  is a confidential  communication  of AIM  Immuno Tech Inc.  It is provided for the 
conduct of  a clinical research study. The information contained in this document is confidential 
and, except to the extent necessary to obtain informed consent or IEC/IRB approval, cann ot be 
disclosed unless required by [CONTACT_26463]. Persons to whom any portion of the contents 
of this document is disclosed must be informed that the information is confidential and may not 
be further disclosed by [CONTACT_476].  

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 2 of 96 
  PROTOCOL APPROVAL  PAGE   
   
 Protocol Number:   AMP -518 
 Version:   Version 4.0 
 Date:    23-Aug-[ADDRESS_536001] reviewed this protocol and agree that it contains all relevant information 
required to meet FDA, GCP and all applicable regulatory guidelines and statutes.  
PROTOCOL APPROVAL  FOR USE  
 
 
    
 
Program Director; Amarex Clinical Research, LLC   Signature   [CONTACT_424176];  Amarex Clinical Research, 
LLC.  
  Signature   [CONTACT_424177]; Amarex Clinical Research, LLC.  
  Signature   [CONTACT_424178]; Amarex Clinical Research, LLC.  
  Signature   [CONTACT_424179] ; AIM 
ImmunoTech Inc.  
  Signature    [CONTACT_424180] # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 3 of 96 
  INVESTIGATOR’S  SIGNATURE  [CONTACT_424181]:   AMP -518 
 Version:   Version 4.0 
 Date:   23-Aug-[ADDRESS_536002] of this clinical trial.  I also agree to comply with US Food and 
Drug Administration (FDA)  regulations  and Investigational Review Board /Institutional Ethics  
(IRB /IEC ) requirements for testing on human subjects.  I agree to ensure that the requirements for 
obtaining informed consent are met .  
 
 
   
Principal Investigator’s Signature  
 
 
  [CONTACT_424182] # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 4 of 96 
 SPONSOR INFORMATION   
 Sponsor  Office:   AIM ImmunoTech Inc.  
      [ADDRESS_536003]  RESEARCH ORGANIZATION INFORMATION  
Amarex Clinical Research, LLC  
Amarex Office:  Amarex  Clinical Research , LLC  
 [ADDRESS_536004] Manager:     
Telephone number:   
Fax number:   
E-mail:   
 
 
Safety/Pharmacovigilance  
Contact :    
[CONTACT_424155]:    
Fax number:     
E-mail:    
  
      

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-[ADDRESS_536005]  ................................ ......................... 25 
 Summary of Prior Pre -Clinical and Clinical Studies  ................................ ........................... 26 
  
  
  
  
  
2. STUDY OBJECTIVES AND OUTCOME MEASURES  ................................ ................... 39 
 Study Objectives  ................................ ................................ ................................ .................. 39 
2.1.1.  Primary Objective ................................ ................................ .............................. 39 
 Study Outcome Measures  ................................ ................................ ................................ ....39 
2.2.1.  Primary Outcome Measure  ................................ ................................ ................ 39 
2.2.2.  Secondary Outcome Measures  ................................ ................................ .......... 39 
2.2.3.  Exploratory Endpoints  ................................ ................................ ....................... 39 
2.2.4.  Safety Outcome Measures  ................................ ................................ ................. 40 
3. STUDY DESIGN  ................................ ................................ ................................ .................... 41 
 Study Center  ................................ ................................ ................................ ........................ 41 
 Study Population  ................................ ................................ ................................ ................. 41 
 Eligibility Criteria  ................................ ................................ ................................ ................ 41 
3.3.1.  Inclusion Criteria  ................................ ................................ ............................... 41 
3.3.2.  Exclusion Criteria  ................................ ................................ .............................. 42 

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 14 of 96 
4. STUDY SCHEDULE  ................................ ................................ ................................ ............. 45 
 Screening Phase  ................................ ................................ ................................ ................... 52 
4.1.1.  Screening Visit (V1)  ................................ ................................ .......................... 52 
 Treatment Phase  ................................ ................................ ................................ .................. 53 
4.2.1.  Randomization (V2)  ................................ ................................ .......................... 53 
4.2.2.  Subsequent Treatment Visits (V3 -V25)  ................................ ............................ 54 
 Follow -Up Phase  ................................ ................................ ................................ ................. 55 
4.3.1.  Follow -Up visit 1 (V26)  ................................ ................................ .................... 55 
4.3.2.  Follow -Up visit 2 (V27)  ................................ ................................ .................... [ADDRESS_536006] Withdrawal From Study  ................................ ................................ ......................... 58 
 Data Collected from Treatment Discontinued/Withdrawn Study Subjects  ......................... [ADDRESS_536007]  ................................ ................................ .......... 60 
6.1.1.  Packaging and Labeling  ................................ ................................ .................... 60 
6.1.2.  Storage and Handling  ................................ ................................ ........................ 60 
 Administration  ................................ ................................ ................................ ..................... 60 
6.2.1.  Study Personnel  ................................ ................................ ................................ .62 
 Drug Compliance  ................................ ................................ ................................ ................ 63 
 Concomitant Medications  ................................ ................................ ................................ ....63 
  
7. DESCRIPTION OF PROTOCOL ASSESSMENTS AND PROCEDURES  ................... 64 
 Informed Consent  ................................ ................................ ................................ ................ 64 
 Assessment of Eligibility  ................................ ................................ ................................ .....64 
7.2.1.  Re-screening  ................................ ................................ ................................ ......64 
 Demographic Information  ................................ ................................ ................................ ...65 
 Medical History  ................................ ................................ ................................ ................... 65 

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 15 of 96 
 Physical Examination  ................................ ................................ ................................ .......... 65 
 Vital Signs, Height and Weight  ................................ ................................ ........................... 66 
 30 Minute Site Check  ................................ ................................ ................................ .......... 67 
 Concomitant Medication  ................................ ................................ ................................ .....67 
 Clinical Laboratory Assessments  ................................ ................................ ........................ 67 
  
 
  
 Pulse oxygen saturation (SpO2)  ................................ ................................ .......................... [ADDRESS_536008]  ................................ ................................ ................................ ............. 70 
 Montreal Cognitive Assessment  ................................ ................................ .......................... 70 
8. STATISTICAL ANALYSIS  ................................ ................................ ................................ .71 
 Treatment Groups  ................................ ................................ ................................ ................ 71 
 Description Of Study Outcomes and Estimand  ................................ ................................ ...71 
 Sample Size Determination and Rationale  ................................ ................................ .......... 72 
 Randomization and Stratification  ................................ ................................ ........................ 72 
 Blinding  ................................ ................................ ................................ ............................... 72 
 Time to Unblinding  ................................ ................................ ................................ ............. 73 
8.6.1.  Emergency Unblinding ................................ ................................ ...................... 73 
8.6.2.  Final Analysis  ................................ ................................ ................................ ....73 
 Interim Analysis  ................................ ................................ ................................ .................. 73 
 General Statistical Considerations  ................................ ................................ ....................... 73 
8.8.1.  Analysis Populations  ................................ ................................ ......................... 73 
8.8.2.  Covariates  ................................ ................................ ................................ .......... 74 
8.8.3.  Missing Data ................................ ................................ ................................ ......74 

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-[ADDRESS_536009] Disposition ................................ ................................ ............................ 75 
8.9.2.  Demographic and Baseline Characteristics  ................................ ....................... 75 
8.9.3.  Concomitant Medications/Therapi[INVESTIGATOR_014]  ................................ ................................ .75 
8.9.4.  Efficacy Analyses  ................................ ................................ .............................. 75 
8.9.5.  Safety Analyses  ................................ ................................ ................................ .76 
9. SAFETY REPORTING ................................ ................................ ................................ ......... 78 
 Adverse event (AE) Definition  ................................ ................................ ............................ [ADDRESS_536010] on Study Treatment  ................................ ................................ ............... 78 
9.2.2.  CTCAE Grade (Intensity) Assessment ................................ .............................. 78 
9.2.3.  Causality Assessment  ................................ ................................ ........................ 79 
9.2.4.  Treatment Given as a Result of the Event  ................................ ......................... 80 
9.2.5.  Outcome Assessment  ................................ ................................ ........................ 80 
 Serious Adverse Event (SAE) Definition  ................................ ................................ ............ 80 
 Reporting of Serious Adverse Events  ................................ ................................ ................. 81 
9.4.1.  SAE Follow -Up ................................ ................................ ................................ .81 
 Expected/anticipated events  ................................ ................................ ................................ [ADDRESS_536011] ACCESS TO SOURCE DATA/DOCUMENTATION  ................................ ......83 
11. QUALITY CONTROL AND QUALITY ASSURANCE  ................................ ................... 84 
 Monitoring Requirements  ................................ ................................ ................................ ....84 
 Acceptability of Case Report Forms (CRFs)  ................................ ................................ ......84 
 Modification of Protocol  ................................ ................................ ................................ .....84 
 Reporting Protocol Deviations  ................................ ................................ ............................ 85 
11.4.1.  Major Protocol Deviation or Violation  ................................ ............................. 85 
11.4.2.  Minor Protocol Deviation or Violation  ................................ ............................. 85 
12. ETHICS AND REGULATORY REQUIREMENTS  ................................ ......................... 87 
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-[ADDRESS_536012]/Independent Ethics Committee (IRB/IEC)  ............................. 87 
 Investigator’s Responsibilities  ................................ ................................ ............................ [ADDRESS_536013] KEEPI[INVESTIGATOR_1645]  ................................ ................................ 89 
 Recording and Collection of Data  ................................ ................................ ....................... 89 
 Clinical Data Management  ................................ ................................ ................................ ..89 
 Archiving  ................................ ................................ ................................ ............................. 90 
14. PUBLICATION PLAN  ................................ ................................ ................................ ......... 91 
15. REFERENCES  ................................ ................................ ................................ ....................... 92 
16. APPENDIX  ................................ ................................ ................................ ............................. 95 
 Appendix 1: Common Terminology Criteria for Adverse Events v5.03  ............................ 95 
 Appendix 2: PROMIS® Sleep Disturbance – Short Form 4a  ................................ .............. 95 
 Appendix 3: PROMIS® Cognitive Function - Abilities short form 8a  ................................ .95 
 Appendix 4: PROMIS® Fatigue Scale ................................ ................................ ................. 95 
 Appendix 5: Symptom Burden Questionnaire for Long COVID (SBQ -LC) ...................... 95 
 Appendix 6: PHQ -9 Patient Depression Questionnaire  ................................ ...................... 95 
 Appendix 7: [ADDRESS_536014]  ................................ ................................ ........................ 95 
 Appendix 8: Montreal Cognitive Assessment (MoCA)  ................................ ...................... 95 
 Appendix 9: Holiday/Vacation Week Visit Scheduling Guidance Document  .................... 96 
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-[ADDRESS_536015] OF FIGURES  
   
   
 
  
  

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-[ADDRESS_536016] Research Organization  
CRS  Cytokine Release Syndrome  
CS Clinically Significant  
CTCAE  Common Terminology Criteria for Adverse Events  
CTMS  Clinical Trial Management System  
DIS Diagnostic Interview Schedule  
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form  
EOT  End of Treatment  
ETT Exercise Tolerance Testing  
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-[ADDRESS_536017] Exertional Malaise  
PCR  Polymerase Chain Reaction  
PHQ  Patient Health Questionnaire  
PI [INVESTIGATOR_424146] # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-[ADDRESS_536018]  Upper Limit of Normal  
[LOCATION_003]  [LOCATION_002] of America  
WBC  White Blood Cells  
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-[ADDRESS_536019] and reporting of this study  shall be conducted in compliance with the protocol, 
International Conference on Harmonization/Good Clinical Practice ( ICH/GCP ), and all 
appropriate regul atory requirements. I nvestigator (s) participating in this study will ha ve 
documented training in GCP. Independent monitoring of the trial will be accomplished utilizing a 
Contract Research Organization (CRO).  
 BACKGROUND OF THE COVID -19 DISEASE  
Severe acute respi[INVESTIGATOR_6507] 2 (SARS -CoV -2), the viral cause of coronavirus 
disease 2019 ( COVID -19) was first identified in late 2019 in Wuhan, Hubei province, China. On 
11 March 2020, the World Health Organization declared the disease a global pandemic. The global 
burden of SARS CoV -2 infection continues to increase with estimates of more than 200 million 
people infected and over four million deaths as of September 2021 . 
While some individuals infected with SARS -CoV -2 may be asymptomatic, many  people display 
symptomatic disease varying from mild to critical in severity. Severe -to-critical illness is typi[INVESTIGATOR_424147]. Morbidity and mortality 
rates are elevated among patients with pre -existing co -morbidities such as cardiovascular disease, 
diabetes mellitus, chronic respi[INVESTIGATOR_3765], hypertension and cancer. The observed case fatality 
ratio (CFR) varies conside rably from country to country and over time. However, the CFR in the 
[LOCATION_003] has been estimated at 2.8%. While public discourse on COVID -19 has largely centered 
around patients with severe or fatal illness, it has become apparent that a growing number of 
patie nts experience mild to moderate symptoms for a prolonged period of time.  
Patients and survivors of COVID -19 from the Body Politic COVID -19 Support Group created and 
analyzed a survey targeted at patients experiencing symptoms for over two weeks. Responses from 
640 patients were collected between April 21 and May 2, 2020 
(https://patientresearchcovid19.com/research/report -1/). 
Key findings were symptoms are not limited to cough, fever, and shortness of breath. Other widely 
reported symptoms span neurological, gastrointestinal, cardiovascular, and other systems and 
include fatigue (reported by 81.3% of respondents), chills/sweats  (75.9%), body aches (73.9%), 
headache (72.2%), brain fog and concentration issues (68.6%), gastrointestinal issues (66.9%), 
trouble sleepi[INVESTIGATOR_007] (66.1%), and dizziness (60.6%). An elevated temperature under 100.1°F was 
reported by 72.2% of respondents while a  fever over 100.1°F was reported by [INVESTIGATOR_13701] 47.8% of 
respondents. The other key finding was recovery is volatile, includes relapses, and can take six or 
more weeks. At the time respondents took the survey, 90.6% reported not being recovered and 
were, on avera ge, on day 40 of experiencing symptoms. 89% of respondents said that their 
symptoms fluctuated in intensity and frequency, and 70% reported new symptoms appearing at 
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-[ADDRESS_536020]-COVID Conditions [ Post-COVID Conditions CDC ].  Although most people 
with COVID -[ADDRESS_536021] had severe illness, these symptoms can happen to anyone who has had COVID -
19, even if the illness was mild, or if they had no initial symptoms. People common ly report 
experiencing different combinations of the following symptoms:  
• Difficulty breathing or shortness of breath  
• Tiredness or fatigue  that interferes with daily life  
• Symptoms that get worse after physical or mental a ctivities (also known as post -exertional 
malaise)  
• Difficulty thinking or concentrating (sometimes referred to as “brain fog”)  
• Cough  
• Chest pain  
• Stomach pain  
• Headache  
• Fast-beating or pounding heart (also known as heart palpi[INVESTIGATOR_814])  
• Joint or muscle pain  
• Pi[INVESTIGATOR_2115]-and-needles feeling  
• Diarrhea  
• Sleep problems  
• Fever  
• Dizziness on standing (lightheadedness)  
• Rash  
• Depression or anxiety  
• Change in smell or taste  
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 29 of 96 
 
  
  
 
 
 
 
 
 
 
 
  
 
 
  
  
  
  
 
 
 
 
  

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 31 of 96 
  
  
 
  
 
 
 
 
 
 
 
 
 
  
 
  
  
 
 
   
  
 
 
 
 
 
   
 
   
 
   
 
 
   

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 32 of 96 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
          
   
 
 
 
 

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 37 of 96 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 39 of 96 
2. STUDY  OBJECTIVE S AND OUTCOME MEASURES  
 STUDY OBJECTIVES  
2.1.1.  Primary Objective  
The purpose of this study is to assess the efficacy and safety  of Ampligen® administered twice 
weekly by [CONTACT_424156]-COVID Condition  of fatigue . 
 STUDY OUTCOME MEASURES  
2.2.1.  Primary Outcome Measure  
• Change from baseline to week 13 in PROMIS® Fatigue Score (T -Score).  
2.2.2.  Secondary Outcome Measures  
• Change from baseline to week 6 in PROMIS® Fatigue Score (T -Score).  
Note: Additional PROMIS® Fatigue Score analysis (change from baseline) at week 6 and 
13 will be performed excluding response to item, “How often did you have enough energy 
to exercise strenuously?”  
• Change from baseline to week [ADDRESS_536022].  
• Proportion of subjects with minimal clinically important difference (MCID), defined as at 
least [ADDRESS_536023] (6MWT) at the end of 12 -week treatment phase.  
• Change from baseline to week 6 and 13 in PROMIS® Cognitive Function Score (T -Score).  
• Change from baseline to week 6 and 13 in PROMIS® Sleep Disturbance Score (T -Score).  
2.2.3.  Exploratory Endpoints  
• Changes from baseline in COVID -19-related symptoms using Symptom Burden 
Questionnaire for Long COVID (SBQ -LC) during the course of the treatment phase.  
Note: A set of common COVID -19-related symptoms (see Symptom Burden Questionnaire 
for Long COVID (SBQ -LC)) will be evaluated at each scheduled study visit by [CONTACT_424157] a subject had at baseline, as new symptoms may appear 
following the baseline assessment.  
• Change from baseline in cognitive function as measured by [CONTACT_424158] (MoCA) at week 4, 8, and 13 during the treatment phase.  
• Incidence of hospi[INVESTIGATOR_424148].  
• Duration (days) of hospi[INVESTIGATOR_424148].  
• Evaluation of lymphocyte profile by [CONTACT_424159] -COVID -19 
conditions . 
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 40 of 96 
• Identification and evaluation of plasma protein biomarkers in patients with post -COVID -
19 conditions.  
2.2.4.  Safety Outcome Measures  
• Incidence of treatment -related adverse events.  
• Incidence and severity of treatment -emergent adverse events (TEAEs).  
• Incidence of  serious adverse events (SAEs).  
• Incidence of TEAEs and SAEs leading to discontinuation of study medication.  
• Changes in blood chemistry, hematology, and coagulation parameter results.  
• Changes in vital signs including temperature, pulse, respi[INVESTIGATOR_697], systolic and diastolic 
blood pressure.  
• Changes in physical examination results.  
• Change in electrocardiogram (ECG) results.  
 
 
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 41 of 96 
3. STUDY  DESIGN   
This is a Phase 2, two -arm, randomized, double blind, placebo controlled multicenter study to 
evaluate the efficacy and safety of Ampligen® in patients experiencing the Post-COVID Condition  
of fatigue . Patients will be randomized 1:1 to receive twice weekly  IV infusions of Ampligen® or 
placebo.  
 STUDY CENT ER 
Up to [ADDRESS_536024] the capability of implementing appropriate 
infection -control measures to prevent infection of study staff and others who share the clinical site 
space.  The facility should be adequately staffed by [CONTACT_424160] a “crash 
cart” in the event of acute allergic reaction or requirement for advanced cardiac life support.  
 STUDY POPULATION  
The study population for the study will be  adult patients with the Post-COVID Condition  of 
fatigue . 
 ELIGIBILITY CRITERIA  
3.3.1.  Inclusion Criteria  
Potential subjects are required to meet all of the following criteria for enrollment into the study : 
1. Male or female adult between 18 to 60 (inclusive) years of age at time of enrollment.  
2. Prior confirmed COVID -[ADDRESS_536025] 12 weeks prior to baseline.  
Note: For  subjects with COVID -[ADDRESS_536026] for SARS -CoV -2 will be sufficient  in subjects 
not vaccinated for COVID -19 or it can be shown that the positive antibody cannot be 
associated with the COVID -19 vaccination . 
3. Laboratory confirmed negative SARS -CoV -2 (COVID -19) infection by a government 
approved test / kit at time of enrollment.  
4. Subject meets for the criteria of fatigue per the 1994 CDC Case Definition for Chronic 
Fatigue Syndrome (CFS):  Unexplained persistent or relapsing chronic fatigue that is of new 
or definite onset (i.e., not lifelong), is not the result  of ongoing exertion, is not substantially 
alleviated by [CONTACT_9075],  and results in substantial reduction in previous levels of occupational, 
educational, social, or personal activities.  The fatigue  must have persisted or recurred during 
[ADDRESS_536027] preceded the onset of the 
COVID -19 symptoms . 
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 42 of 96 
5. PROMIS® Fatigue - Short Form 7a response total  raw score of ≥21 at screening and 
baseline.  
6. Electrocardiogram (ECG) with no clinically significant findings as assessed by [CONTACT_3786].  
  Note: Below are the examples of clinically significant ECG abnormalities:  
− Previous documented evidence of myocardial infarction or recent significant change 
in the resting EKG suggesting infarction or other acute cardiac events.  
− Current symptoms of coronary insufficiency (i.e. - angina pectoris and/or ST segment 
depression on EKG).  
− Evidence of uncontrolled atrial or frequent or complex ventricular ectopy, or 
myocardial conduction defect which would increase the risk of syncope (for example, 
second degree or higher A -V block).  
7. Subject (or legally authorized representative) provides written informed consent prior to 
initiation of any study procedures.  
8. Men and women of childbearing potential and their partner must agree to use two medically 
accepted methods of contraception (e.g., barrier contraceptives [male condom, female 
condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, 
injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], 
or one of the following methods of birth control (intrauterine devices, bilateral tubal 
occlusion, or vasectomy) or must practice complete sexual abstinence for the  duration of 
the study (excluding women who are not of childbearing potential and men who have been 
sterilized).  
9. Females of child -bearing potential must have a negative urine pregnancy test at Screening 
Visit and prior to receiving the first dose of study drug; and Male participants must agree 
to use contraception and refrain from donating sperm for at least [ADDRESS_536028] is willing and able to comply with scheduled visits, drug administration plan, 
laboratory tests, other study procedures and study restrictions.  
3.3.2.  Exclusion Criteria  
Potential subjects meeting any of the following criteria will be excluded from enrollment:  
1. Inability to provide informed consent or to return to the Investigator’s site for scheduled 
infusions and evaluations.  
2. Exhibiting signs of moderate or severe pulmonary disease (such as COPD, asthma, or 
pulmonary fibrosis).  
3. Ongoing requirement of oxygen therapy.  
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 43 of 96 
4. Pulse oxygen saturation (SpO2) of <94% on room air at the time of screening.  
5. Thrombocytopenia (platelets <100×109/L), anemia  (hemoglobin <9.0 g/dL) , or leukopenia  
(WBC <3×109/L) on screening labs  
6. History of splenectomy.  
7. Known hypercoagulable state or at increased risk of thrombosis (e.g., due to immobility)  
8. Liver cirrhosis or patient showing signs of clinical jaundice at the time of screening.  
9. Transaminase (ALT or AST) >3X ULN or total bilirubin >2X ULN at screening  
10. Chronic kidney disease stage 4 or requiring dialysis at the time of screening.  
11. Estimated GFR <60 mL/min/1.73 m2 at the time of screening   
12. NYHA Class III or IV congestive heart failure (CHF).  
13. Exhibiting signs of uncontrolled hypo -or hyper -thyroidism at the time of Screening.  
14. Diagnosis of autoimmune disease (e.g., SLE, rheumatoid arthritis, psoriasis) at the time of 
screening   
15. Uncontrolled rheumatologic disorders at the time of screening.  
16. Diagnosis of sleep apnea (central or obstructive) at the time of screening.  
17. History of organ transplantation or are candidates for organ transplantation at the time of 
screening.  
18. History of Chronic Fatigue Syndrome prior to COVID -[ADDRESS_536029] give written informed consent prior 
to discontinuation of investigational drugs.  
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 44 of 96 
25. Treatment with any of the following therapi[INVESTIGATOR_424149] (8) weeks immediately 
preceding the start of study baseline or during baseline: systemic glucocorticoids (i.e., 
hydrocortisone, prednisone, etc.) or mineralocorticoids (i.e., fludrocortisone (Florinef), 
etc.), interfero ns, interleukin -2, systemic antivirals, gamma globulin or investigational 
drugs or experimental agents not yet approved for use in the [LOCATION_002].  
26. Prior participation in an Ampligen® study.  
27. Medical necessity, as determined by [CONTACT_102]’s primary doctor or the principal 
investigator, to continue aspi[INVESTIGATOR_248] (ASA) or non -steroidal anti -inflammatory (NSAID) drugs 
for 20 consecutive days or for more than 10% of the study duration.  
28. History of congestive heart failure , suspected or known dissecting aneurysm, recent 
systemic or pulmonary embolus or myocardial infarction  (≤ 6 months) , severe  valvular heart 
disease, ventricular aneurysm, active or suspected myocarditis or pericarditis, 
thrombophlebitis or intracardiac thrombi, or acute infection.  
29. Evidence of moderate or severe obstructive pulmonary disease.  
30. Resting diastolic blood pressure > 115 mm Hg or resting systolic blood pressure > 200 mm 
Hg. 
31. Uncontrolled metabolic disease (e.g., diabetes, thyrotoxicosis, or myxedema ). 
32. Concurrent use of any beta blockers and/or bronchodilators which cannot remain at a stable 
dosage level during baseline and the study.  
33. History of alcohol or other substance abuse within two (2) years before the onset of acute 
COVID -[ADDRESS_536030].  
34. History of suicidal ideation , suicide attempt , or suicidal behavior  within two (2) years of 
baseline.  A score of [ADDRESS_536031]. A score of greater than zero on question nine (9) of 
the PHQ -[ADDRESS_536032] feeding.  
36. Participation in another study for an investigational treatment.  
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-[ADDRESS_536033] three phases: Screening Phase, Treatment Phase, and Follow -Up Phase.  
Note: During visits conducted at the study clinic, subjects and site personnel will use appropriate 
protective gear (e.g., masks, gloves) to prevent the spread of the infection.  
Screening Phase (up to 1 week):  
All subjects will provide written informed consent and have a Screening visit (V1) within [ADDRESS_536034] treatment visit (V2) to determine eligibility for subject participation.  
All subjects who fail to meet eligibility criteria are considered screen failures and are exited from 
the study without further evaluation.  
Treatment Phase (12 weeks):  
Ampligen® and placebo will be administered via twice weekly infusions (Example: 
Monday/Thursday or Tuesday/Friday schedule) for 12 weeks.  
 
 
   
 
Follow -Up Phase  (2 weeks):  
Two safety follow -up visits will be performed 3 to 4 days and 2 weeks after the End of Treatment 
(EOT) visit (V25).  

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL  Page 51 of 96 
  
 
 
  
 
 
  
 
  
  
 
     
  
 
 

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 52 of 96 
 SCREENING PHASE  
Screening  phase is designed to determine  whether subjects are eligible to proceed to the treatment  
phase of the study.  
4.1.1.   Screening Visit (V1)  
Screening assessments will commence at Visit 1 (V1) after obtaining signed informed consent, 
and will include :  
  
   
   
  
  
  
  
  
   
  
  
 
   
  
  
  
   
  
  
All subjects who fail to meet eligibility criteria are considered screen failures and are exited from 
the study without further evaluation.  
 
 

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 53 of 96 
 
 
  
 
 
 TREATMENT PHASE  
4.2.1.  Randomization (V2)  
Visit 2 (Day 0) defined as day of first Ampligen® or placebo administration . 
Subjects who meet the eligibility criteria will have completed the following evaluations and 
assessments at V2:  
  
  
  
   
  
  
  
   
   
   
  
   
   
    
  
   
 
   
  

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 55 of 96 
  
   
  
  
 
   
  
 
  
   
 
    
   
  
  
  
   
  
 
   
  
  
   
 
 
 
 
 
    
 FOLLOW -UP PHASE  
4.3.1.  Follow -Up visit  1 (V26)  

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 56 of 96 
Follow -Up visit (V26) will be performed 3 or 4 days after the End of Treatment (EOT) visit (visit 
25). The following assessments will be performed at V26:  
  
    
    
    
  
   
  
   
  
   
   
  
  
  
  
   
4.3.2.  Follow -Up visit 2 (V27) 
Follow -Up visit 2 will be performed at 2 weeks after the End of Treatment (EOT) visit (visit 25). 
The following assessments will be performed at V27:  
   
   
   
   
  
  
  
   

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 57 of 96 
   
  
   
   
  
 UNSCHEDULED VISITS  
In the event  that the subjec t will return  to clinic  at a time other than  a regularly  scheduled  study  
visit,  the visit will be regarded  as an unscheduled  visit.  Assessments at unscheduled visits are at 
the discretion of the Investigator.  All pertinent findings, including  adverse events or changes in 
medications, will be noted in the eCRF.  

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-[ADDRESS_536035] who completes the Treatment  Phase will be considered as having completed the study.  
Note: Subjects who discontinue treatment (voluntarily or involuntarily) or withdrawn from study 
participation prior to completing visit [ADDRESS_536036] TREATMENT DISCONTINUATION  
Patients who fail to comply with the requirements of the study will be discontinued  from the study 
treatment .  Reasons for treatment discontinuation  may include but are not limited to the following:  
• Lost to Follow -up 
• Voluntary patient or guardian  withdrawal . 
• Protocol violation, such as failure to comply with the requirements of the study or use of 
prohibited concomitant medications.  
• Physician decision, such as significant intercurrent illness or surgery, as determined by [CONTACT_424161], or which requires 
administration of drugs disallowed in this study.  
• Adverse event, such as toxicity grading of 3 or 4 or serious adverse event (SAE) felt by [CONTACT_424162] . 
 SUBJECT WITHDRAWAL FROM STUDY  
Subjects should only be considered withdrawn from the study if they withdraw consent.  
 DATA COLLECTED FROM TREATMENT DISCONTINUED /WITHDRAWN STUDY SUBJECTS  
Every attempt should be made to collect follow -up information  for the subjects who discontinued 
the treatment or were withdraw n from the study .  
 
 
 
 
 
 
 
  

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-[ADDRESS_536037] adhere to the 
Good Clinical Practice (GCP) i n the process of obtaining and documenting the informed consent . 
The Investigator, or designee, must also inform subjects of all pertinent aspects of the study. Before 
written informed consent is obtained from the subject, the Investigator  or a person designated by 
[CONTACT_737], must provide the subject enough time and opportunity  to inquire about the details 
of the study and to deci de whether or not to participate in the trial. All questions addressed by [CONTACT_424163]. Prior to the subject’s 
participation in the trial, the written informed consent must be signed and personally dated by [CONTACT_177157]. Author ization for 
release of protected health information must also be obtained, as per local policies .  
 ASSESSMENT OF ELIGIBILITY  
The Investigator must assess subject continued eligibility for the study as per the Inclusion and 
Exclusion criteria, during the Screening Phase. The  eligibility  criteria are described in Section 
3.3.1  (Inclusion Criteria) and Section 3.3.2  (Exclusion Criteria) . In the event that the subject is not 
suitable or eligible for the study,  the subject will be considered “ screen failure ”.  
7.2.1.  Re-screening  
A subject who signed a consent form but did not meet the inclusion/exclusion criteria is classified 
as a screen failure.  
 
 
 
 
 
 
 
 
 
 

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 65 of 96 
 DEMOGRAPHIC INFORMATION  
In this study the  demographic information will include:  
• Dates of ICF signature  
• Date of birth  
• Gender  
• Race (American Indian  or Alaska Native, Asian, Black or African American, Native 
Hawaiian  or Other Pacific Islander, White , Not Reported,  or Unknown ) 
• Ethnicity (Hispanic  or Latino , Not Hispanic  or Latino , Not Reported, or Unknown ) 
• Use of tobacco products  
 MEDICAL HISTORY  
A medical history will be recorded during the Screening Phase and will include:  
• All ongoing medical conditions  
• All previously resolved medical conditions that are relevant in the judgment of the 
Investigator  
• Any prior medical conditions that have resolved within the last year  
Events that emerge prior to first dose of study medication on Day [ADDRESS_536038]’s receiving investigational product treatment.  
For each relevant history, the following will be documented:  
• Disease/disorder/condition  
• Date of diagnosis  
• History status (resolved or ongoing ). 
 PHYSICAL EXAMINATION  
The physical examination will include routine examinations for the following:  
• Constitutional/General Appearance  
• Head, Ears, Eyes, Nose, Throat (HEENT)  
• Neurologic  
• Cardiovascular  
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 66 of 96 
• Musculoskeletal and Extremities  
• Dermatologic  
• Respi[INVESTIGATOR_696]  
• Gastrointestinal  
• Genitourinary  
• Lymphatic  
• Psychiatric  
Each abnormality will be recorded,  and the Investigator will record an assessment of its clinical 
significance.  
 VITAL SIGNS , HEIGHT AND WEIGHT  
The following will be collected:  
• Systolic Blood Pressure  
• Diastolic Blood Pressure  
• Heart Rate  (Pulse)  
• Temperature  
• Respi[INVESTIGATOR_696] R ate  
• Height  (Screening only)  
• Weigh t 
• Body Mass Index  
Note: During days of Ampligen® or Placebo administration, pre-infusion  vitals  (before the 
start of infusion ) and post -infusion  vitals  (after the end of infusion ) will be measured. Post -
infusion vitals will be limited to blood pressure  and pulse  only. 
Note:  During study visits  when the 6MWT is performed , vitals should be collected before and 
after 6MWT (i.e., pre 6MWT, and post 6MWT ), as clinically indicated per  the discretion of 
the Investigator or designee . These should be documented in the source records  as standard of 
care assessments ; however, they will not be captured as a protocol assessment.  
Note: During study visits when the 6MWT and study drug administration is performed (i.e., 
Visit 6, 12, and 18), vitals should be collected as follows: pre 6MWT and post 6MWT, if  
clinically indicated per the discretion of the Investigator or designee. Subjects should be rested 
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-[ADDRESS_536039] ed in the source documents and on the 
appropriate page of the case report form (CRF). Subjects must be questioned at each study visit 
concerning any new medications or changes in current medications including over -the-counter 
medication and topi[INVESTIGATOR_73201].  
For each medication and non -study treatment, the following will be documented:  
• Medication/treatment name (generic name [CONTACT_26499])  
• Dose, unit, and frequency of dosing (individual dosages, not total daily dose).  
o Note:  Each new dose of medication should be recorded as a separate entry, with 
the exception of medications that are given on a sliding scale. For these, it is 
acceptable to enter the range of the dosage, including the start and stop dates for 
which the specifie d dosage range was used.  
• Route of dosing   
• Indication for use  
• The start date  
• The stop date (if medication/therapy is not ongoing) .  
 CLINICAL LABORATORY ASSESSMENTS  
Blood samples will b e collected for analysis of the following parameters  described in Table 
7-1 (local lab) and Table 7-2 (central lab) .  
 
 
  

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 71 of 96 
8. STATISTICAL ANALYSIS  
This Section  presents general information about statistical considerations and concepts and a brief 
discussion on analysis methodology, as well as some data conventions. Detailed descriptions of 
the statistical analysis methods and data conventions that will be used i n this study will be in a 
separate document,  i.e., the Statistical Analysis Plan (SAP).  
 TREATMENT GROUPS  
The following treatment groups will be assessed in the study:  
• Ampligen®  
• Placebo  (normal saline)  
 DESCRIPTION OF STUDY OUTCOMES  AND ESTIMAND   
Refer to Section 2.2 for description of study outcome measures.  
 
    
 
 
 
 
 
  
   
  
 
 
 
 
      
 
 
  
 
 
 
      
      
 

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 72 of 96 
  
 
  
 
   
 
   
 
 
 SAMPLE SIZE DETERMINATION AND RATIONALE  
The sample size of  80 subjects will be used in this study. The sample size is based on clinical 
judgment. No statistical power calculation is used to establish the sample size for this proof -of-
concept study.  
 RANDOMIZATION  AND STRATIFICATION  
A total of 80 subjects (40 per group) will be randomized in a 1:1 ratio (Ampligen®: placebo). 
 
  
  
 
 
 
 
 
 BLINDING  
This is a double -blind  study . The investigator and staff, subjects and Sponsor/CRO staff directly 
related to study conduct will be blinded to the treatment assignment.   
 
 
 
 
.  

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-[ADDRESS_536040]’s well -being requires knowledge 
of the subject’s treatment allocation. Every attempt will be made to maintain the blind throughout 
the study.  
 
 
 
 
 
 
            
 
 
 
 
  
 
 
 
 
 INTERIM ANALYSIS  
There is no planned  interim analysis for this early phase study . 
 GENERAL STATISTICAL CONSIDERATIONS  
All collected study data will be presented in subject data listings.  
  
 
 
8.8.1.  Analysis Populations  
  

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 74 of 96 
 
 
  
 
  
 
 
  
 
 
   
 
8.8.2.  Covariates  
For efficacy analyses important prognostic factors that need adjustment will be specified in the 
Statistical Analysis Plan  (SAP) for the study.  
8.8.3.  Missing Data  
All efforts will be made to avoid missing data; however,  there will be no imputation of missing 
data for this early phase study and primary analysis of efficacy data will be based on observed data 
only. 
 
 
 
 
 
 
 
 
  
8.8.4.  Multiplicity  
No adjustment of multiplicity will be done for the efficacy analysis of the data for this early phase 
study . 
 ANALYSIS METHODS  

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 75 of 96 
A Statistical Analysis Plan (SAP) will be developed and approved before the database is locked. 
The SAP will present the detailed statistical methodology to be used in analyzing the data from 
this trial.  
8.9.1.  Subject Disposition  
The disposition of all subjects who signed an ICF will be provided.  
 
 
 
 
8.9.2.  Demographic and Baseline Characteristics  
Demographics and baseline characteristics  will be summarized by [CONTACT_276196].  
Medical history  will be presented as by -subject listing.  
8.9.3.  Concomitant Medications/Therapi[INVESTIGATOR_11535]/therapi[INVESTIGATOR_11536]. All 
prior and concomitant medications recorded in the case report form will be coded to matching 
Anatomic Therapeutic Classification codes using the most recent vers ion of the WHO Drug 
Dictionary. Descriptive summaries by [CONTACT_424164]. All 
concomitant medications/therapi[INVESTIGATOR_11537].  
8.9.4.  Efficacy Analyses  
[IP_ADDRESS].  Primary Analysis   
 
  
 
 
  
 
 
  

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 76 of 96 
•   
  
   
  
  
  
  
  
   
  
   
 
 
  
8.9.5.  Safety Analyses   
[IP_ADDRESS].  Adverse Events  
Adverse events will be classified by [CONTACT_9313] (SOC) and preferred term (PT) according 
to the most recent version of MedDRA dictionary.     
 
 
 
  
  
  
  
  
[IP_ADDRESS].  Clinical Laboratory Data  
 
 
 
 

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 77 of 96 
[IP_ADDRESS].  Vital signs  
 
 
 
[IP_ADDRESS].  Physical Examination  
  
[IP_ADDRESS].  ECG  
 
 
 

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 78 of 96 
9. SAFETY REPORTING   
The Investigator is responsible for the detection and documentation of events meeting the criteria 
and definition of an AE or SAE, as provided in this protocol. During the study when there is a 
safety evaluation, the Investigator or site staff will be resp onsible for detecting, documenting,  and 
reporting AEs and SAEs as detailed in this Section of the protocol.  
 ADVERSE EVENT (AE)  DEFINITION   
An adverse event (AE)  is defined as any unfavorable or unintended sign, symptom, or disease that 
occurs or is reported by [CONTACT_11563], or a worsening of a pre -existing condition. 
An adverse event may or may not be related to the study treatment.  
AEs will be elicited through direct questioning and subject reports. Any abnormality in physical 
examination findings or laboratory results that the investigator believes is clinically significant  
(CS)  to the research subject and that occurred after initiation of the first study treatment will be 
reported as AEs. Abnormal findings that are NOT clinically significant should not be recorded as 
an AE.  
 REPORTING OF ADVERSE EVENTS  
Report initiation for all AEs and SAEs  will begin at the time of the first treatment  visit and continue 
until the end of final study visit. All events will be followed to resolution or until the subject 
completes the study. A final assessment of outcome will be made at that time.  
All AEs must be recorded in the subject’s medical records and on the CRF. AEs will be reported 
using customary medical terminology along with the following information: the onset and end 
dates,  whether the event is considered to be a n SAE (see Section 9.3), the impact the event had on 
study treatment (see Section 9.2.1 ), the Common Terminology Criteria for Adverse Events 
(CTCAE) grade (intensity) of the event (see Section 9.2.2 ), the causality of the event (see Section 
9.2.3 ), whether treatment was given as a result of the event (see Section 9.2.4 ), and the outcome 
of the event (see Section 9.2.5 ) 
9.2.1.  Impact on Study Treatment  
The impact the event had on the study treatment will be assessed as either: dose increased, dose 
not changed, dose rate reduced, dose reduced, drug interrupted, drug withdrawn, not applicable, 
or unknown . The “not applicable” assessment will be used only when the subject is no longer in 
the Treatment Phase of the protocol . 
9.2.2.  CTCAE Grade (Intensity) Assessment  
The guidelines outlined in CTCAE v 5.0 will be used for assessing the intensity of the event. The 
general guidelines for assessing the AE grade appear below.  Full guidelines may be obtained at 
http://evs.nci.nih.gov/ftp1/CTCAE . 
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-[ADDRESS_536041]’s clinical state, environmental or toxic factors, or other 
therapi[INVESTIGATOR_26455]. (3) Disappears or is decreased upon discontinuation of 
the study treatment. (4) It follows a known response pattern to t reatment with the study 
treatment.  
4. Unlikely  related : In general,  this category can be considered applicable to those AEs which, 
after careful medical consideration at the time they are evaluated, are judged likely to be 
unrelated to the study treatment. An AE may be considered unlikely if or when (must have 
two): (1) i t does not follow a reasonable temporal sequence from administration of the study 
treatment. (2) It could not readily have been produced by [CONTACT_1130]’s clinical state, environmental 
or toxic factors, or other therapi[INVESTIGATOR_424150]. (3) Disappears or is decreased 
upon discontinuation of the study treatment. (4) It does not follow a known response pattern 
to treatment with the study treatment.  
5. Unrelated : This category applies to those AEs which, after careful consideration at the time 
they are evaluated, are clearly and incontrovertibly due to extraneous causes (disease, 
environment, etc.) and determined with certainty to have no relationship to the stud y treatment.  
9.2.4.  Treatment Given as a Result of the Event  
The event impact in terms of treatment provided will be as either: none, medication administered, 
non-drug therapy administered, surgery performed, hospi[INVESTIGATOR_059], or other (with a specification).  
9.2.5.  Outcome Assessment  
The outcome of the event will be assessed as either: fatal, not recovered/not resolved, 
recovered/ resolved, recovered/ resolved with sequelae, recovering/resolving , or unknown . Only 
one AE per subject is allowed to have an outcome assessment as “death.” If there are multiple 
causes of death for a given subject, only the primary cause of death will have an outcome of death.  
 SERIOUS ADVERSE EVENT  (SAE)  DEFINITION  
An SAE is defined as any AE that:  
• Results in death  
• Is life threatening (the subject is at immediate risk of dying from the adverse experience)  
• Requires subject hospi[INVESTIGATOR_72010]  
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth defect  
• Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_3767] a serious adverse effect when, based upon appropriate 
medical judgment, they may jeopardize the subject or subject and may require medi cal or 
surgical intervention to prevent one of the outcomes listed in this definition . 
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 81 of 96 
 REPORTING OF SERIOUS ADVERSE EVENTS    
The Investigator is required to report all SAEs that occur during the time period specified in  
Section 9.2. Once the Investigator becomes aware of an SAE, he/she must report the SAE to 
Medical Monitor  within [ADDRESS_536042] additional supporting documentation as it becomes available, 
such as lab reports, electrocardiogram [ECG] reports, discharge summary, hospi[INVESTIGATOR_11533], etc., if 
applicable. Additional follow -up information as it becomes available must be reported to the 
Medical Monitor . 
The Investigator is also responsible for reporting all SAEs to the appropriate Institutional Review 
Board (IRB) in accordance with local laws and regulations. The Investigator is responsible for 
maintaining documentation in the study file that indicates th e IRB has been properly notified.  
9.4.1.  SAE Follow -Up 
All subjects experiencing an SAE, including the discontinued subjects, must be closely followed 
until sufficient information is obtained to indicate a return to normal status or until the event 
stabilizes at a level acceptable to the investigator (i.e., re covery, return to baseline status, no further 
improvement expected, or death).  
For each SAE indicated as an unresolved event on the initial report, regardless of whether the 
subject completed the study or withdrew, the site should submit a follow -up report with updated 
information . 
 EXPECTED /ANTICIPATED EVENTS  
Refer to Investigator Brochure for the expected/antic ipated events.  
 PREGNANCY REPORTING  
To ensure patient safety, any pregnancy that occurs  after the first treatment visit until the end of 
final study visit should be recorded using a Pregnancy Notification Form and reported immediately 
to Sponsor within 24 hours of learning of the pregnancy.  

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-[ADDRESS_536043] interfered 
with the effectiveness of a contraceptive medication. Congenital abnormalities/birth defects and 
spontaneous miscarriages should be reported and handled a s SAEs.  
[IP_ADDRESS].  Abortions  
An induced elective abortion to terminate a pregnancy without medical reason is not regarded as 
an AE. However, an induced therapeutic abortion to terminate a pregnancy because of 
complications or medical reasons must be reported as an SAE. The underlying medical diagnosis 
for this procedure should be reported as the SAE term. A spontaneous abortion in a study subject 
is always considered an SAE.  
9.6.2.  Informed Consent  
The ICF will include information regarding reporting of pregnancy to the Sponsor and collection 
of information through the end of pregnancy that occurs in either a female subject or in a female 
partner of a male subject. If a female partner becomes pregnan t, the Investigator will request 
consent from the partner to collect this information.  
9.6.3.  Pregnancy Follow -Up 
The pregnancy will be followed -up to determine the outcome (spontaneous miscarriage, elective 
termination, ectopic pregnancy, normal birth, or congenital abnormality) and should include an 
assessment of the possible relationship to the study treatment of any pregnancy outcome. This 
information should also be documented on the Pregnancy Outcome Form and reported to the 
Sponsor.  
 
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-[ADDRESS_536044] ACCESS TO SOURCE DATA/DOCUMENTATION  
Subjects will be identified on eCRFs by a unique subject identification number and on source 
documents by [CONTACT_11572]. No personal identifier will be used in any publication or 
communication used to support this research study. The subject identification number will be used 
if it becomes necessary to identify data specific to a single subject.  
The local IRB, FDA , the monitors, auditors,  and personnel authorized by [CONTACT_424165] . They  will be given direct access to source data and 
documentation (e.g., medical charts/records, printouts etc.) for source data verification, provided 
that subject confidentiality is maintained in accordance with local requirements. Access to 
electronic medic al records  may be governed by [CONTACT_11573] . The study  site will be required 
to ensure access while remaining compliant with institutional requirements.  
 
 
 
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 84 of 96 
11. QUALITY CONTROL AND QUALITY ASSURANCE  
 MONITORING REQUIREMENTS  
The specific obligations outlined in 21 Code of Federal Regulations ( CFR ) and ICH guidelines 
require  the Sponsor to maintain current personal knowl edge of the progress of a study. Therefore,  
the Sponsor's designated monitor will vis it the site  during the study as well as maintain frequent 
telephone and written communication. The Investigator will permit the Sponsor to monitor the 
study as frequently as is deemed necessary and provide access to medical records to ensure that 
data are being recor ded adequatel y, that data are verifiable,  and that protocol adherence is 
satisfactory.  
As delineated above, t he Investigator will permit representatives of the Sponsor and/or designated 
CRO to inspect all CRFs and corresponding study subject original medical records (source 
documents) at regular intervals throughout the study. Subject original medical records and  other 
relevant data must be available to support all data recorded in the eCRF. In addition to the original 
medical records, these data may include but are not limited to  study, laboratory reports, etc.  
In accordance with federal regulations, s ite inspections will serve to verify strict adherence to the 
protocol and the accuracy of the data that is being e ntered on the case report forms . A Monitoring 
Log will be maintained at each study site . The Monitoring Log  will be signed by [CONTACT_2037] , 
dated,  and state d the type of visit. The Investigator should be aware that the study site and subject 
records may be inspected by [CONTACT_424166], FDA or 
other regional regulatory authority.  
 ACCEPTABILITY O F CASE REPORT FORMS (CRF S) 
For each subject who has signed an informed consent form, a CRF  must be completed. For subjects 
who are screen failures, this would be limited to the screen failure CRF page. All source documents 
and CRFs will be completed as soon as pos sible after the subject's visit and c orrections to data on 
the CRFs will be documented , if applicable . The Investigator will review the CRFs to indicate that, 
to his/her knowledge, they are complete and accurate. CRFs will be reviewed by [CONTACT_1034]’s or 
designated CRO’s mon itor, who will make a decision as to their acceptability.   
 MODIFICATION O F PROTOCOL  
The Investigator will not modify or alter this protocol without first o btaining the concurrence of 
the Sponsor. Approval by [CONTACT_737]’s IRB must also be obtained prior to implementation of 
the change, with two exceptions:  
1. When necessary to eliminate apparent immediate hazard to the subject; or  
2. When the modification does not involve the subject’s participation in the trial.  
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-[ADDRESS_536045]'s rights, safety, or well-being  and/or the completeness, accuracy,  and reliability 
of the study data.  Examples of this include:  
• Failure to obtain informed consent prior to initiation of study -related procedures  
• A research subject does not meet the protocol's eligibility criteria but was enrolled without 
prior approval from the sponsor.  
• A research subject received the wrong treatment or incorrect dose.  
• A research subject met withdrawal criteria during the study but was not withdrawn.  
• A research subject received a  prohibited  concomitant medication.  
• Failure to treat research subjects per protocol procedures that specifically relat e to primary 
efficacy outcomes.  
• Changing the protocol without prior  sponsor and  IRB approval.  
• Multiple minor violations of the same nature after multiple warnings.  
11.4.2.   Minor Protocol Deviation or Violation  
A minor protocol deviation is any change, divergence, or departure from the study design or 
procedures of a research protocol that has not been approved by [CONTACT_424167] a major impact on the subject's rights, safety or well -being, or the  completeness, accuracy,  
and reliability of the study data.  Examples of this include:  
• Follow -up visits that occurred outside the protocol required time frame because of the 
participant’s schedule.  
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 86 of 96 
• Blood samples obtained at times close to but not precisely at the time points specified in the 
protocol.  
 
 
 
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 87 of 96 
12. ETHIC S AND REGULATORY REQUIREMENTS  
This study is to be conducted in accordance with the specifications of this protocol and in 
accordance with principles consistent with Declaration of Helsinki,  GCP, 21 CFR , ICH E6, 
HIPAA regulations in 45 CFR Part 164 (US only), and the Belmont Principles of respect for 
persons, beneficence, and justice. No protocol changes will be implemented without the prior 
review and approval of the IRB, except when the modification doe s not involve the subject’s 
participation in the trial or where it may be necessary to eliminate an immediate hazard to a 
research subject. In the latter case, the change will be reported to the IRB as soon as possible, 
according to IRB regulations.  
Additionally, the study product  used in this study is manufactured, handled,  and stored in 
accordance with applicable GMP . The study product  provided for this study will be used only in 
accordance with this protocol.  
 INSTITUTIONAL REVIEW BOARD /INDEPENDENT ETHICS COMMITTEE  (IRB/IEC)  
The Principal Investigator (PI) at each site wi ll provide the Institutional Review 
Board/Independent Ethics Committee (IRB/IEC) with all appropriate materials as required by [CONTACT_162500]/IEC, including but not limited to the clinical study protocol, informed consent form, and any 
advertising materials. Th e study will not be initiated until the IRB/IEC provides written approval 
of the aforementioned documents and until approval documents have been obtained by [CONTACT_1268] [INVESTIGATOR_424151]. The Investigator will not participate in 
the decision. If the Investigator is an IRB or IEC member, documentation must be provided 
indicating recusal from the approval process. Appropriate reports on the progress of this study by 
[CONTACT_424168]/IEC as required by [CONTACT_424169]. The Investigator 
is required to maintain an accurate and complete record of all written correspondence to and 
received from the IRB/ IEC and  must agree to share all such documents and reports with the 
Sponsor.  
No changes from the final approved protocol will be initiated without the IRB/IEC’s prior written 
approval or favorable opi[INVESTIGATOR_1101] a written amendment, except when necessary to eliminate 
immediate hazards to the subjects or when the modification does not i nvolve the subject’s 
participation in the trial.   
 INVESTIGATOR ’S RESPONSIBILITIES  
The Investigators are responsible for performing the study in full accordance with the protocol and 
the current revision of the Declaration of Helsinki, the Good Clinical Practice: Consolidated 
Guideline, approved by [CONTACT_11580], and any applicable national an d local laws and regulations. 
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-[ADDRESS_536046] INFORMED CONSENT REQUIREMENTS  
All subjects participating in this study will be given to by [CONTACT_11219]/or designee, w ritten 
and oral information about the study in a language understandable by [CONTACT_423]. Written informed 
consent will be obtained from each subject prior  to any procedures or assessments that would not 
otherwise be required for the care of the subject are done and after the aims, methods, anticipated 
benefits, potential hazards, and insurance arrangements in force are explained and the subject has 
been given s ufficient time to ask questions and consider participation in the study. It will also be 
explained to the subjects that they are free to refuse entry into the study and free to withdraw from 
the study at any time without prejudice to future treatment. It is permissible for a third person (e.g., 
a family member) to be present during the explanation of the study.  
The written Informed Consent Form (ICF) will be in compliance with CFR 21 Part 50.27 and GCP 
guidelines. The Sponsor and/or designated CRO will approve the ICF and all amendments to the 
ICF prior to submission to the IRB/IEC. A copy of the ICF to be used will be submitted by [CONTACT_24657]/IEC for review and approval prior to the start of the study. The study site 
must provide the Sponsor with an unsigned copy of IRB/IEC -approved ICF along with applicable 
documentation to support this approval.  The original signed ICF is retained in the subject's study 
records, and a copy is provided to the subject. A second copy may be filed in the subject’s medical 
record, if allowed by [CONTACT_10569].  
 
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-[ADDRESS_536047]'s medical record. If separate 
research records are maintained by [CONTACT_737](s), the medical record and the research records 
will be considered the source documents for the purposes of aud iting the study.  
Applicable source data will be manually transcribed to approve  case report forms (CRF). The 
Investigator is ultimately responsible for the accuracy of the data transcribed on the forms. All 
source documents and CRFs will be completed as soon as possible after the subject's visit.  
The Investigator will review the CRFs to indicate that, to his/her knowledge, they are complete 
and accurate. Designated source documents will be signed and dated by [CONTACT_162929]. The Investigator must agree to complete and maintain source documents and CRFs for 
each su bject participating in the study.  
All research data will be entered, either electronically or manually, into a computerized database. 
The clinical database will be designed by [CONTACT_424170] [ADDRESS_536048]’s 
study number, name, date of birth, and unique hospi[INVESTIGATOR_11538]. This 
list will be kept by [CONTACT_424171]. A notation will be 
made in the subject’s case history/medical chart that he/she is participating in a clinical study and 
has provided a signed and dated ICF as well as a release for protected health information as 
required by [CONTACT_5737] p olicies. The Investigator must also maintain a separate screening log of all the 
subjects screened for participation in the study; it should include gender, age, eligibility status,  
reason for ineligibility, if applicable; and study allocated subject number, if applicable.  
 CLINICAL DATA MANAGEMENT  
The Sponsor and/or designated CRO will be responsible for the processing and quality control of 
the data. Data management will be carried out as described in the Sponsor’s or CRO’s standard 
operating procedures (SOPs) for clinical studies.  
The handling of data, including data quality control, will comply with regulatory guidelines 
(e.g.,  ICH E6 GCP, and local regulations where applicable) and the Sponsor’s or the CRO’s SOPs 
as well as provisions of the study -specific Data Management Plan.  
 
 
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 90 of 96 
 ARCHIVING  
All study documentation at the Investigator site and Sponsor site will be archived in accordance 
with ICH GCP E6 and the Sponsor’s quality standards and SOPs.  
The Investigator will maintain all research records, reports, and case history reports for a period 
of two  (2) years after regulatory approval of the investigational product.  If no application is filed 
or if the application is not approved, records must be maintained for two  (2) years after all 
investigations have been completed, terminated or discontinued and the FDA has been notified.  
These documents should be retained for a longer period however, if required by [CONTACT_424172] ( as per 
GCP  5.5.11 ). 
At the completion of the study, details of the archival process must be provided to the Sponsor. 
Study records are subject to inspection by [CONTACT_11583].  
Records to be retained by [CONTACT_11584], but are not restricted to:  
• Source data and the primary records upon which they are based (e.g., subject’s progress 
notes, adverse event data, test results, and any other diagnostic procedures required to 
evaluate the progress of the study)  
• Completed CRFs  
• Signed protocols and protocol amendments  
• Laboratory results, ranges, and certifications  
• IP and accountability records  
• Study personnel signature [CONTACT_26500]  
• Monitoring logs  
• Correspondence to and from the Sponsor, designee,  and IRB  
• Investigator and sub -investigator CVs  
• Signed informed consent and protected health information consent forms  
• Subject screening  
• SAE reports  
• IRB approval and re -approval letters  
• Complete d quality of life questionnaire  
• Other documents pertaining to the conduct of the study  
These documents must be maintained and kept on file by [CONTACT_424173].  
Study records should not be transferred from site or destroyed without prior written agreement 
between the Sponsor and the study Investigator. Study records are subject to inspection by 
[CONTACT_11583].  
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 91 of 96 
14. PUBLICATION PLAN  
All information  supplied  by [CONTACT_424174]. in connection  with this study  and not 
previously  published,  is considered  confidential  information.  This information  includes,  but is 
not limited  to, the Investigator ’s Brochure,  clinical  protocol,  case report  forms  and other  
scientific  data.  Any data collected  during  the study  are also considered  confidential.  This 
confidential  information  shall  remain  the sole property  of AIM ImmunoTech  Inc., shall  not be 
disclosed  to others  without  the written  consent  of AIM ImmunoTech  Inc., and shall  not be used 
except in the performance of this study.  
It is understood by [CONTACT_424175]. Therefore , this 
information may be disclosed as required to other Investigators or appropriate regulatory 
authorities. By [CONTACT_320214], the Investigator understands that he/she 
has an obligation to provide the Sponsor with complete test results and all data developed during 
this trial.  
Publication and Disclosure : The s ite and Investigator agree to submit any proposed manuscript, 
presentation,  or other public disclosure regarding the study to Sponsor for review at least thirty 
(30) days prior to submitting such proposed manuscript to a publisher or delivering or making such 
presentation or other public disclosure to any third party. Within thir ty (30) days of its receipt, 
Sponsor shall advise the site and/or Investigator, as the case may be, in writing of any information 
contained therein that is confidential information (other than research results included in a 
proposed manuscript) or that may impair Sponsor’s ability to obtain patent protection. Sponsor 
shall have the right to require the site and/or Investigator, as applicable, to remove specifically 
identified confidential information (but may not require removal of research results from a 
proposed manuscript) and/or to delay the proposed submission or delivery of the proposed 
manuscript or presentation, or other public disclosure, for an additional sixty (60) days to enable 
Sponsor to seek patent protection. The s ite and Investigator shall not publish, publicly disclose, 
present or discuss any results of or information pertaining to the site’s and Investigator’s activities 
prior to completion of the trial, even if the study is terminated before its completion and the final 
clinical study report is signed off, or with respect to any endpoints or analyses other than those 
specified in this protocol.  
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 92 of 96 
15. REFERENCES  
Aldinucci, D. and Colombatti, A., 2014. The inflammatory chemokine CCL5 and cancer 
progression. Mediators of inflammation, 2014. Alexander SV, Philipp G, Marion S, Joachim SH, 
Anton SH, Max S, Matthias K, Boris B. von Bergwelt -Baildon Michael S. Cytokine release 
syndrome. J. Immunotherapy Cancer. 2018;6(1).  
Ampligen® in HIV Disease:  Monotherapy and Cohort Analysis, July 27, 1990.  HEM Research 
Report.  
Barnard , D.L., et al. Proceedings of the 16th International Conference on Antiviral Research, 
[ADDRESS_536049] , D.L.; Day, C.W.; Bailey, K.; Heiner, M.; Montgomery, R.; Lauridsen, L.; Chan, P.K.; 
Sidwell, RW.  Evaluation of immunomodulators, interferons and know n in vitro SARS -CoV 
inhibitors for inhibition of SARS -CoV replication in BALB/c mice. Antivir Chem Chemother, 
2006 , 17(5), 275 -84. 
Data on file, AIM ImmunoTech Inc.  
Day, C.W.; Baric, R.; Cai, S.X.; Frieman, M.; Kumaki, Y.; Morrey, J.D.; Smee, D.F.; Barnard, 
D.L. A new mouse -adapted strain of SARS -CoV as a lethal model for evaluating antiviral 
agents in vitro and in vivo. Virology, 2009 , 395(2), 210 -222. 
de Vega WC, Herrera S, Vernon SD, McGowan PO. Epi[INVESTIGATOR_424152]/chronic fatigue syndrome (ME/CFS). BMC Medical 
Genomics. 2017 Dec 1;10(1):11.  
Fundenberg HH.  The Florence Nightingale Disease (FND):  A Multisystem Experiment of 
Nature:  A 50 Patient Five Year Analysis.  In:  Hyde B, ed.  The Clinical and Scientific Basis of 
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, 641 -653.  The Nightin gale Research 
Foundation, Ottawa, Ontario, 1992.  
Greenstone , H, Experiment No NIAS 178, 24Aug2007.  
Hives L., Bradley A., Richards J. Can physical assessment techniques aid diagnosis in people 
with chronic fatigue syndrome/myalgic encephalomyelitis? A diagnostic accuracy study. BMJ 
Open. 2017;[ADDRESS_536050] 
Neurobiol. 1993;19:480 –488. Montoya JG.  
Law HKW, Cheung CY, Ng HY, et al. Chemokine up -regulation in SARS -coronavirus -infected, 
monocyte -derived human dendritic cells. Blood 2005;106:2366 -2374.  
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 93 of 96 
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current 
concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 
10;124(2):188 -95. 
Marra, MA, Jones, SJM, Astell, CR, et al., The Genome Sequence of the SARS -Associated 
Coronavirus, Science, 2003, 300(5624) 1399 -1404, DOI: 10.1126/science.1085953  
Mogensen TH, Paludan SR. Molecular pathways in virus -induced cytokine production. 
Microbiology and Molecular Biology Reviews. 2001 Mar 1;65(1):[ADDRESS_536051] -SARS syndrome; a case -controlled study. BMC Neurol. 
2011;11:1 –7. 
Montoya JG, Holmes TH, Anderson JN, Maecker HT, Rosenberg -Hasson Y, Valencia IJ, Chu L, 
Younger JW, Tato CM, Davis MM. Cytokine signature [CONTACT_424183]. Proceedings of the National Academy of Sciences . 2017 Aug 
22;114(34):E7150 -8. 
Morris G, Maes M, Berk M, Puri BK. Myalgic encephalomyelitis or chronic fatigue syndrome: 
how could the illness develop?. Metabolic Brain Disease. 2019 Apr;34(2):385 -415. 
Palaiodimos L, Kokkinidis DG, Karamanis LW et al. Severe obesity, increasing age and male sex 
are independently associated with worse in -hospi[INVESTIGATOR_95209], and higher mortality, in a cohort 
of patients with COVID -19 in the Bronx, [LOCATION_001]. Metabolism 2020;108:154262. 
Doi:10.1016/j.metab.2020.154262.  
Perrin R, Riste L, Hann M, et al. Into the looking glass: Post -viral syndrome post COVID -19. 
Med Hypotheses 2020;144:110055. doi.org/10.1016/j.mehy.2020.110055.  
Quin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y. Dysregulation of immune response in patients 
with COVID -[ADDRESS_536052] dis. 2020;248:1 -7. 
Rasa S, Nora -Krukle Z, Henning N, Eliassen E, Shikova E, Harrer T, Scheibenbogen C, 
Murovska M, Prusty BK. Chronic viral infections in myalgic encephalomyelitis/chronic fatigue 
syndrome (ME/CFS). Journal of Translational Medicine. 2018 Dec 1;16(1):268.  
Sotzny F, Blanco J, Capelli E, Castro -Marrero J, Steiner S, Murovska M, Scheibenbogen C. 
Myalgic encephalomyelitis/chronic fatigue syndrome –evidence for an autoimmune disease. 
Autoimmunity Reviews. 2018 Jun 1;17(6):601 -9. 
Steiner S, Becker SC, Hartwig J, Sotzny F, Lorenz S, Bauer S, Löbel M, Stittrich AB, Grabowski 
P, Scheibenbogen C. Autoimmunity -related risk variants in PTPN22 and CTLA4 are associated 
with ME/CFS with infectious onset. Frontiers in Immunology. 2020;11.  
Strayer DR, Carter WA, Brodsky I, Cheney P, Peterson D, Salvato P, Thompson C, Loveless M, 
Shapi[INVESTIGATOR_424153], Elsasser W and Gillespie DH.  A controlled clinical trial with specifically configured 
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 94 of 96 
RNA drug, poly(I) poly(C 12U), in chronic fatigue syndrome.  Clinical Infectious Diseases 
18(suppl 1):S88 -S95, 1994.  
Strayer DR, Carter W, Strauss KI, Brodsky I, Suhadolnik RJ, Ablashi D, Henry B, Mitchell WM, 
Bastien S and Peterson D.  Long term improvement in patients with chronic fatigue syndrome 
treated with Ampligen®.  J Chronic Fatigue Syndrome, 1:[ADDRESS_536053] rintatolimod in severe cases 
of chronic fatigue syndrome. PLoS ONE 2012 ;7(3):e31334.  
Strayer, DR, Dickey, R, Carter, WA, Sensitivity of SARS/MERS CoV to Interferons and Other 
Drugs Based  on Achievable Serum Concentrations in Humans, Infectious Disorders – Drug 
Targets, 2014, Vol. 14, No.[ADDRESS_536054], Stouch BC, Stevens SR, Bateman L, Lapp CW, Peterson DL. Chronic fatigue 
syndrome/myalgic encephalomyelitis (CFS/ME): characteristics of responders to rintatolimod. J 
Drug Res Dev. 2015;1(1):[ADDRESS_536055], Young  D, and Mitchell  WM. "Effect of disease duration in a randomized Phase III 
trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue 
Syndrome." PloS one 15.10 (2020): e0240403.  
Yen, Yu -Ting, et al. "Modeling the early events of severe acute respi[INVESTIGATOR_424154]." Journal of virology 80.6 (2006): 2684 -2693.  
 
  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 95 of 96 
16. APPENDIX  
 APPENDIX 1: COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS V 5.03 
For complete detailed information please refer to the link below : 
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_R
eference_5x7.pdf  
 APPENDIX  2: PROMIS® SLEEP DISTURBANCE – SHORT FORM 4A 
Appendix 2 found here.  
 APPENDIX 3: PROMIS® COGNITIVE FUNCTION - ABILITIES SHORT FORM 8A 
Appendix 3 found here.  
 APPENDIX  4: PROMIS® FATIGUE SCALE  
Appendix 4 found here.  
 APPENDIX  5: SYMPTOM BURDEN QUESTIONNAIRE FOR LONG COVID  (SBQ -LC) 
Appendix 5 found here.  
 APPENDIX 6: PHQ -9 PATIENT DEPRESSION QUESTIONNAIRE  
Appendix 6 found here.  
 APPENDIX 7: 6-MINUTE WALK TEST 
For complete detailed information please refer to the link below:  
https://neuropt.org/docs/default -source/cpgs/core -outcome -measures/core -outcome -measures -
drafts--march -2018/6mwt_protocol_final.pdf?sfvrsn=36cd5443_4  
 APPENDIX 8: MONTREAL COGNITIVE ASSESSMENT  (MOCA) 
 
 
 
  
 
 

  Protocol # AMP -518 
                                                                                                   Version 4.0 
Date:  23-Aug-2023  
CONFIDENTIAL      Page 96 of 96 
 APPENDIX 9: HOLIDAY /VACATION WEEK VISIT SCHEDULING GUIDANCE DOCUMENT  
Appendix 9 found here.  
 
 